FDA Establishes Import Alert 66-80 Targeting Unapproved GLP-1 API Suppliers on Quality Grounds

FDA's activation of import alert 66-80 for GLP-1 active pharmaceutical ingredients signals a direct enforcement posture toward foreign API manufacturers operating outside demonstrable GMP compliance, a development with immediate supplier qualification implications for any facility compounding semaglutide or tirzepatide.

The alert targets APIs with potential quality concerns at the border, preventing their entry into the U.S. supply chain. Critically, the measure does not restrict importation from manufacturers that have passed an FDA inspection or equivalent agency evaluation. The distinction matters operationally: supplier qualification files that lack documented FDA inspection history or equivalent compliance evidence are now a material gap, not a procedural formality.

Cold-chain integrity has emerged as a parallel enforcement focus. FDA has received complaints that compounded injectable GLP-1 products arrived warm or with inadequate refrigeration, conditions that compromise sterility assurance and drug quality. Injectable GLP-1 drugs require refrigeration per their package inserts, and the agency has stated directly that products arriving outside those temperature parameters should not be used. For QA directors managing contract compounders or third-party logistics providers, shipping SOP validation and temperature excursion documentation warrant immediate review against 21 CFR Part 211 storage and distribution requirements.

Fraudulent labeling adds a third dimension to the compliance picture. FDA has identified compounded semaglutide and tirzepatide products carrying false pharmacy identifiers, in some cases naming pharmacies that do not exist, in others attributing product to licensed facilities that did not compound it. One adverse event report linked to a fraudulently labeled tirzepatide product included injection-site reactions: redness, swelling, pain, and a subcutaneous lump. The presence of counterfeit product in the channel raises chain-of-custody questions that extend upstream to distributor qualification and lot traceability protocols.

FDA is coordinating with state regulatory partners on compounding oversight and has indicated it will continue direct communication with compounders regarding identified concerns. Facilities operating under ICH Q10 pharmaceutical quality system frameworks should treat the import alert as a signal to reassess API supplier risk ratings and confirm that incoming material testing programs are calibrated to detect quality deviations that uninspected foreign manufacturers may not control.

The measurable checkpoint ahead is supplier qualification audit completion against the updated import alert criteria, with particular attention to whether current API vendors appear on FDA's compliant-manufacturer list or carry documented inspection outcomes sufficient to clear the alert threshold.

Source: FDA Drugs, Drug Alerts and Statements via FDA.gov, May 26, 2026.